Evidence map›Paper›PMID 39714621›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Machine learning in personalized laryngeal cancer management: insights into clinical characteristics, therapeutic options, and survival predictions.

Sakhr Alshwayyat, Tamara Feras Kamal, Tala Abdulsalam Alshwayyat, Mustafa Alshwayyat, Hamdah Hanifa, Ramez M Odat, Miassar Rawashdeh, Alia Alawneh, Kholoud Qassem

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sakhr AlshwayyatResearch Associate, King Hussein Cancer Center, Amman, Jordan.ORCID http://orcid.org/0000-0002-2295-1945
Tamara Feras KamalFaculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan.
Tala Abdulsalam AlshwayyatPrincess Basma Teaching Hospital, Irbid, Jordan.ORCID http://orcid.org/0009-0009-1754-2395
Mustafa AlshwayyatFaculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan.
Hamdah HanifaFaculty of Medicine, University of Kalamoon, Al-Nabk, Syria. hamdahhanifa@gmail.com.ORCID http://orcid.org/0000-0003-2970-7379
Ramez M OdatFaculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan.ORCID http://orcid.org/0009-0008-3423-4055
Miassar RawashdehDivision of Otolaryngology, Department of Special Surgery, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Alia AlawnehInternal Medicine Department, Palliative Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Kholoud QassemKing Hussein Cancer Center, Medical Oncology Department, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOver the last 40 years, there has been an unusual trend where, even though there are more varied treatments, survival rates have not improved much. Our study used survival analysis and machine learning (ML) to investigate this odd situation and to improve prediction methods for treating non-metastatic LSCC.

methodsThe surveillance, epidemiology and end results (SEER) database provided the data used for this study's analysis. To identify the prognostic variables for patients with non-metastatic LSCC, we conducted Cox regression analysis and constructed prognostic models using five ML algorithms to predict 5-year survival. A method of validation that incorporated the area under the curve (AUC) of the receiver operating characteristic (ROC) curve was employed to validate the accuracy and reliability of the ML models. We also investigated the role of multiple therapeutic options using Kaplan Meier (K-M) survival analysis.

resultsThe study included 63,324 patients, of whom 40,824 were diagnosed with glottic cancer (GC), 21,774 with supraglottic (SuGC) and 726 with subglottic (SC). ML models identified age, stage, and tumor size as the most important factors that affect survival. For SuGC, age, stage, and sex and stage and race for SC. In terms of treatment, best survival therapeutic options for GC and SC were surgery and radiotherapy (RT), whereas SuGC surgery only.

conclusionThis study underscores the critical role of individualized factors in non-metastatic LSCC management, with surgery often combined with radiotherapy as the optimal treatment for early stage tumors. Despite advancements, stable prognosis highlights the need for continuous refinement of therapeutic strategies to balance tumor control and quality of life.

Indexed as

Laryngeal NeoplasmsMachine LearningPrecision MedicineAdultAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisSEER ProgramSurvival RateUnited StatesLaryngeal neoplasmsMachine learningPersonalized medicinePrognosisQuality of lifeSurvival analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.